Cadherins, catenins and cell cycle regulators: Impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial

Gynecologic Oncology

Volumn 123, Issue 2, 2011, Pages 320-328

  Singh, Meenakshi ^a   Darcy, Kathleen M ^b   Brady, William E ^b   Clubwala, Rashna ^a   Weber, Zachary ^c   Rittenbach, Jon V ^d   Akalin, Ali ^e   Whitney, Charles W ^f   Zaino, Richard ^g   Ramirez, Nilsa C ^h   Leslie, Kimberly K ⁱ  

^a STONY BROOK UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Providence St Mary Medical Center   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f CHRISTIANA CARE HEALTH SYSTEM   (United States)

^g PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^h THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF IOWA   (United States)

Author keywords

Cadherin; Catenin; Endometrial cancer; p120; p16; p53

Indexed keywords

ALPHA CATENIN; BETA CATENIN; CADHERIN; CATENIN; CD40 ANTIGEN; KI 67 ANTIGEN; MEDROXYPROGESTERONE; NERVE CELL ADHESION MOLECULE; PLAKOGLOBIN; PROTEIN P120; PROTEIN P16; PROTEIN P27; TAMOXIFEN; UVOMORULIN;

ADENOMATOUS POLYP; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE REGULATION; CLINICAL ARTICLE; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POLYPOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CATENINS; CELL CYCLE PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80054741190     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.07.005     Document Type: Article

References (41)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics CA Cancer J Clin 2010
2. S. Hirohashi Inactivation of E-cadherin mediated cell adhesion system in human cancers Am J Pathol 153 1998 333 339
3. M. Takeichi The cadherins: cell-cell adhesion molecules controlling animal morphogenesis Development 102 1988 639 655
4. H. Shiozaki, H. Tahara, H. Oka, M. Miyata, K. Kobayashi, and S. Tamura Expression of immunoreactive E-cadherin molecules in human cancers Am J Pathol 139 1991 17 23
5. S. Miyamoto, H. Baba, S. Kuroda, K. Kaibuchi, T. Fukuda, and Y. Maehara Changes in E-cadherin associated with cytoplasmic molecules in well and poorly differentiated endometrial cancer Br J Cancer 83 2000 1168 1175
6. E. Carico, F. Fulcinti, M.R. Giovagnoli, N.S. Losito, G. Botti, and G. Benincasa Adhesion molecules and p16 expression in endocervical adenocarcinoma Virchows Arch 455 2009 245 251
7. INK4A immunoexpression: surrogate marker for high-risk HPV and high-grade cervical intraepithelial neoplasia Adv Anatomical Pathol 13 2006 190 194
8. INK4A as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri Int J Cancer 92 2001 276 284
9. INK4A overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix Hum Pathol 34 2003 778 783
10. A. Goldstein, M. Fraser, J. Struewing, C.J. Hussussian, K. Ranade, and D.P. Zametkin Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations N Engl J Med 333 1995 970 974
11. J. Hansson Familial cutaneous melanoma Adv Exp Med Biol 685 2010 134 145
12. S. Ozkara, and A. Corakci Significantly decreased p27 expression in endometrial carcinoma compared to complex hyperplasia with atypia (correlation with p53 expression) Pathol Oncol Res 10 2004 89 97
13. P. Athanassiadou, P. Athanassiades, D. Grapsa, M. Gonidi, A.M. Athanassiadou, and P.N. Stamati The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study Int J Gynecol Cancer 17 2007 694 704
14. A. Afify, S. Craig, A.F. Paulino, and R. Stern Expression of hyaluronic acid and its receptors, CD44s, and CD44v6, in normal, hyperplastic, and neoplastic endometrium Annals Diag Pathol 9 2005 312 318
15. K. Banno, M. Yanokura, N. Susumu, M. Kawaguchi, N. Hirao, and A. Hirasawa Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer Oncol Rep 16 2006 1189 1196
16. T. Fukuchi, M. Sakamoto, H. Tsuda, K. Maruyama, S. Nozawa, and S. Hirohashi Beta-catenin mutation in carcinoma of the uterine endometrium Cancer Res 58 1998 3526 3528
17. I. Stefansson, H. Salvesen, and L. Akslen Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer J Clin Oncol 22 2004 1242 1251
18. A.N. Scholten, R. Aliredjo, C.L. Creutzberg, and V.T. Smit Combined E-cadherin, α-catenin, and β-catenin expression is a favorable prognostic factor in endometrial carcinoma Int J Gynecol Cancer 16 2006 1379 1385
19. N. Sakuragi, M. Nishiya, K. Ikeda, T. Ohkouch, E.E. Furth, and H. Hareyama Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion Gynecol Oncol 53 1994 138 139
20. K. Holcomb, R. Delatorre, B. Pedemonte, C. McLeod, L. Anderson, and J. Chambers E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium Obstet Gynecol 100 2002 1290 1295
21. C. Whitney, V. Brunetto, R. Zaino, S.S. Lentz, J. Sorosky, and D.K. Armstrong Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group Study Gynecol Oncol 92 2004 4 9
22. M. Singh, R. Zaino, V. Filiaici, and K.K. Leslie Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study Gynecol Oncol 106 2007 325 333
23. V. Schimp, R. Ali-Fehmi, L. Solomon, A. Hammoud, V. Pansare, and R.T. Morris The racial disparity in outcomes in endometrial cancer: could this be explained on a molecular level? Gynecol Oncol 102 2006 440 446
24. A.S. Lukes, M.F. Kohler, C.F. Pieper, B.J. Kerns, R. Bentley, and G.C. Rodriguez Mutivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer Cancer 73 1994 2380 2385
25. I. Engelsen, I. Stefansson, L. Akslen, and H.Bl. Salvesen Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas Am J Obstet Gynecol 195 2006 979 986
26. L. Nycum, L. Smith, J. Farley, E.R. Kost, M.W. Method, and M.J. Birrer The role of p27 in endometrial carcinoma Gynecol Oncol 81 2001 242 246
27. J. Watanabe, H. Sato, T. Kanai, Y. Kamata, T. Jobo, and H. Hata Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus-correlation with proliferation and clinicopathological parameters Br J Cancer 87 2002 81 85
28. L.K. Mell, J.J. Meyer, M. Tretiakova, A. Khramtsov, C. Gong, and S.D. Yamada Prognostic significance of e-cadherin protein expression in pathological stage I-III endometrial cancer Clin Cancer Res 10 2004 5546 5553
29. Y.T. Kim, E.K. Choi, J.W. Kim, D.K. Kim, S.H. Kim, and W.I. Yang Expression of E-cadherin and alpha-, beta-, gamma-catenin proteins in endometrial carcinoma Yonsei Med J 43 2002 701 711
30. W. McCluggage, and D. Jenkins p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma Int J Gynecol Pathol 22 2003 231 235
31. A. Ignatov, J. Bischoff, C. Schwarzenau, T. Krebs, D. Kuester, and K. Herrmann P16 alterations increase the metastatic potential of endometrial carcinoma Gynecol Oncol 111 2008 365 371
32. B.V. Kallakury, R.A. Ambros, A.M. Hayner-Buchan, C.E. Sheehan, J.H. Malfetano, and J.S. Ross Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes Int J Gynecol Pathol 17 1998 320 326
33. L. Friberg, H. Noren, and U. Dell Prognostic value of DNA ploidy and S-phase fraction in endometrial cancer stage I and II: a prospective 5 year survival study Gynecol Oncol 53 1994 64 69
34. U. Stendahl, P. Strang, G. Wagenius, R. Bergström, and B. Tribukait Prognostic significance of proliferation in endometrial carcinoma: a multivariate analysis of clinical and flow cytometric variables Int J Gynecol Pathol 10 1991 271 284
35. P. Strang, B. Stenkvist, R. Bergström, U. Stendahl, M. Valdes del Campo, and B. Tribukait Flow cytometry in endometrial carcinoma: a comparative and prognostic study Anticancer Res 11 1991 783 788
36. G. Wagenius, R. Bergström, P. Strang, U. Gerdes, K. Rogo, and B. Tribukait Prognostic significance of flow cytometric and clinical variables in endometrial adenocarcinoma stages l and II Anticancer Res 12 1992 725 732
37. A. Ayhan, E. Tok, I. Bildirici, and A. Ayhan Overexpression of CD44 variant 6 in human endometrial cancer and its prognostic significance Gynecol Oncol 80 2001 355 358
38. G.N. Stokes, J.B. Shelton Jr. , C.M. Zahn, and B. Kendall Association of CD44 isoform immunohistochemical expression with myometrial and vascular invasion in endometrioid endometrial carcinoma Gynecol Oncol 84 2002 58 61
39. M. Katsura, H. Furumoto, M. Nishimura, M. Kamada, and T. Aono Overexpression of CD44 variants 6 and 7 in human endometrial cancer Gynecol Oncol 71 1998 185 189
40. M. Saegusa, M. Hashimura, and I. Okayasu CD44 expression in normal, hyperplastic and malignant endometrium J Pathol 184 1998 297 306
41. M. LeBlanc, C. Poncelet, D. Soriano, F. Walker-Combrouze, P. Madelenat, and J.Y. Scoazec Alteration of CD44 and cadherins expression: possible association with augmented aggressiveness and invasiveness of endometrial carcinoma Virchows Arch 438 2001 78 85